<DOC>
	<DOCNO>NCT00098800</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use fenretinide may prevent ovarian cancer . PURPOSE : This randomized clinical trial study well fenretinide work prevent ovarian cancer participant high risk develop ovarian cancer plan undergo surgery remove ovary .</brief_summary>
	<brief_title>Fenretinide Preventing Ovarian Cancer Participants Who Are High Risk Developing Ovarian Cancer Planning Undergo Surgery Remove Ovaries</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare induction apoptosis ( determined TUNEL ) ovarian epithelial stromal cell participant high risk ovarian cancer treat fenretinide v placebo . Secondary - Compare modulation several intermediate marker ( TGFβ , BAX , Ki-67 , ER , PR , RARβ , TGFβRI , TGFβRII , p21 , p53 , FAS , FASL ) participant treat regimen . - Compare early microvascular change , use contrast-enhanced ultrasound , participant treat drug . - Determine whether use contrast agent could indicate change ovarian size architecture may assess potential surrogate preventive effect participant . - Determine feasibility future chemoprevention trial ovarian cancer . - Determine toxicity fenretinide participant . - Compare microvascularity index ovarian volume participant treat drug . - Correlate area increase microvascularity abnormality pathology finding obtain oophorectomy participant treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Participants randomize 1 2 treatment arm . - Arm I : Participants receive oral fenretinide daily . - Arm II : Participants receive oral placebo daily . In arm , treatment continue 6-8 week absence unacceptable toxicity . Within 5 day completion fenretinide placebo , participant undergo bilateral salpingo-oophorectomy . Participants follow 6 week . PROJECTED ACCRUAL : A total 40 participant ( 20 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk develop ovarian cancer , meet 1 follow criterion : Family history ovarian cancer , define ≥ 1 firstdegree relative diagnose ovarian cancer 50 year age Family history ovarian cancer , define ≥ 1 firstdegree relative diagnose ovarian cancer age AND ≥ 1 first seconddegree relative diagnose breast ovarian cancer age Positive BRCA1/BRCA2 test Planning undergo prophylactic bilateral oophorectomy PATIENT CHARACTERISTICS : Age 30 Performance status Zubrod 01 Life expectancy At least 12 month Hematopoietic Not specify Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 1.5 time ULN Alkaline phosphatase ≤ 1.5 time ULN No history liver disease* No cholestatic jaundice No hepatic adenomas NOTE : *For patient undergo contrast enhance ultrasound Renal BUN normal Creatinine normal Cardiovascular No history congenital heart defect create bidirectional righttoleft shunt* No history congestive heart failure* No thrombophlebitis No thromboembolic disease No cerebral vascular disease No coronary artery disease NOTE : *For patient undergo contrast enhance ultrasound Pulmonary No history pulmonary hypertension* No history pulmonary emboli* No history severe emphysema* NOTE : *For patient undergo contrast enhance ultrasound Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception Thyroid stimulate hormone normal T4 normal Triglycerides ≤ 1.5 time ULN No malignancy within past 5 year except breast cancer basal cell squamous cell skin cancer No evidence recurrent disease No known suspect hypersensitivity blood , blood product , albumin No undiagnosed genital bleed No history pancreatitis No uncontrolled diabetes No severe underlie chronic disease No concurrent alcohol use ( &gt; 3 drinks/day equivalent ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 3 month since prior chemotherapy breast cancer Endocrine therapy No concurrent selective estrogenreceptor modulators , include raloxifene No concurrent aromatase inhibitor Radiotherapy Not specify Surgery See Disease Characteristics Other More 3 month since prior therapeutic oral topical vitamin A derivative ( e.g. , isotretinoin ) No concurrent investigational agent No concurrent cyclooxygenase2 ( COX2 ) inhibitors No concurrent oral vitamin A ascorbic acid ( vitamin C ) supplement &gt; recommend daily requirement ( 10,000 IU vitamin A 75 mg vitamin C )</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
</DOC>